(77 days)
K11194-, K11220-
Not Found
No
The summary describes a system with a pressure transducer and a pre-programmed diagnostic computer with a GUI, but there is no mention of AI, ML, or any learning or adaptive capabilities. The performance studies focus on technical success, ease of use, and adverse events, not on the performance of an AI/ML algorithm.
No
The device is intended to facilitate guidewire placement to access the epicardial surface, not to treat a disease or condition.
Yes
The device measures needle tip pressure, and the control unit includes a pre-programmed diagnostic computer and displays pressure frequency information, which aids in assessing access to the pericardial space.
No
The device description explicitly states that the system includes hardware components: a sterile, single-use needle with an integrated pressure transducer and a reusable integrated Control Unit.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is to access the epicardial surface of the heart via a subxiphoid approach to facilitate guidewire placement. This is a surgical/interventional procedure, not a diagnostic test performed on samples taken from the body.
- Device Description: The device is a needle with a pressure transducer and a control unit. This is a tool used during a medical procedure, not a system for analyzing biological samples.
- Anatomical Site: The device interacts directly with the epicardial surface of the heart, which is an internal anatomical site. IVDs typically analyze samples from the body (blood, urine, tissue, etc.).
- Input Imaging Modality: While fluoroscopic imaging is mentioned, it's used to guide the procedure, not as the primary input for a diagnostic test.
- Key Metrics: The key metrics are technical success of the procedure, ease of use, and adverse events. These are related to the performance of the device during the intervention, not the accuracy of a diagnostic result.
IVD devices are specifically designed to perform tests on samples taken from the human body to provide information for the diagnosis, monitoring, or treatment of diseases or conditions. This device does not fit that description.
N/A
Intended Use / Indications for Use
The EpiAccess System with introducer needle and integrated needle tip pressure transducer is intended to access the epicardial surface of the heart via a subxiphoid approach to facilitate guidewire placement into the pericardial space in electrophysiology procedures in adult patients.
Product codes
DYB, DRS, DXG
Device Description
The EpiAccess System consists of the following components and accessories: a sterile, single-use (disposable) Tuohy Type Needle with an integrated, distal, needle tip pressure transducer (sensor), and a reusable integrated Control Unit that includes pre-programmed diagnostic computer with a touchscreen display and graphical user interface (GUI).
The EpiAccess Control Unit provides the EpiAccess System with the additional convenience feature of integrated, direct physiological pressure measurement at the EpiAccess Needle tip. The EpiAccess Control Unit also receives input from commercially available arterial line (A-line) catheters and commercially available A-line pressure transducers. These accessories are readily available standard equipment in electrophysiology labs. A-line catheter pressure measurements are routine in electrophysiology procedures. The A-line pressure measurement function is also provided for user convenience and is displayed along with the needle tip pressure measurement on the EpiAccess user interface.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
epicardial surface of the heart, pericardial space
Indicated Patient Age Range
adult patients
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Bench, animal, and clinical tests were conducted on the EpiAccess System to demonstrate that it meets defined design requirements and can perform in a manner equivalent to devices currently on the market used for subxiphoid epicardial access and that provide pressure measurements. Testing included verification and validation testing, comparative usability testing in animals, human factors evaluations per the available guidances, and an assessment of clinical performance.
Nonclinical testing included:
Dimensional and Performance testing per the applicable sections of ISO 594-2: 1998, SO 594-1: 1986, ISO 7864: 1993, ISO 9626: 2001, BS EN ISO 14971:2012.
Electrical Safety and Electromagnetic Compatibility (EMC) per the applicable sections of ANSI/AAMI/IEC 60601-1-2:2007, IEC 60601-1 3rd Edition:2012, EN 61000 3-2: 2006, EN 61000-3-3: 2008.
Pressure transducer testing per applicable sections of AAMI/ANSI BP22:1994 (R) 2011, IEC 60601-2-34 Edition 3.0 2011-05.
Biocompatibilty Testing per relevant sections of ISO 10993, including: BS EN ISO 10993-11:2009, BS EN ISO 10993-4:2009, BS EN ISO 10993-5:2009, BS EN ISO 10993-10:2009. Biocompatibilty testing passed for patient contacting materials included L929 Neutral Red Uptake Cytotoxicity Test, Kligman Maximization Test, Intracutaneous Injection Test, Systemic Injection Test, Rabbit Pyrogen Test (Material Mediated), Hemolysis Rabbit Blood, Complement Activation Assay, Unactivated Partial Thromboplastin Time Assay.
Sterilization and LAL Pyrogen validation in compliance with applicable sections of ANSI/AAMI/ISO 11135-1:2007, ISO 10993-7: 2008, ANSI/AAMI/ISO 11737-1: 2006, ANSI/AAMI/ISO 11737-2: 2009, AAMI TIR: 16:2000, AAMI ST72: 2002(R) 2010, FDA Guidance (Jun 2012), FDA Guidance (Dec 12, 2008), FDA Guidance (Aug 30, 2002).
Shelf Life and Packaging validation in compliance with applicable sections of ASTM F88-09, ASTM D4169-09, ASTM F1929: 2012, ASTM F1980: 2007, ASTM D5276: 1998, ASTM D642: 2010, ASTM D999:2008, ASTM D6653: 2013, ASTM D4728: 2011, ASTM D6344: 2009.
Software validation in compliance with applicable sections of BS EN ISO 62304:2006, FDA Guidance (Jan 11, 2012), FDA Guidance (Sep 9, 1999).
Comparative Animal Studies in compliance with applicable sections of 21 CRF § 54, FDA Guidance (Jul 29, 2010).
Usability and Human Factors Testing in compliance with applicable sections of SI/AAMI HE 75, IEC 62366:2007, FDA Guidance (Jun 22, 2011).
Clinical data were obtained via the Epicardial Access Study. A Post Market Clinical Follow-up Study -Europe (EASe) (ClincialTrials.gov Identifier: NCT02209064). This is a European study for the purpose of collecting post marketing data of the CE Marked EpiAccess System. The study subjects are eligible adult patients undergoing epicardial electrophysiology procedures accessed via a minimally invasive subxiphoid approach. The study report supporting this notification summarizes and discusses the clinical results, including technical success (ability to safely access the pericardial space and deliver a guidewire), ease of use and clinical benefit of the pressure frequency information display, and adverse events. Clinical testing complies with applicable sections of 42 U.S.C. 282(j), Section 402(j) of the Public Health Serve Act, enacted by 121 Stat. 823 Public Law 110-85, ISO 14155:2011, MEDDEV 2.7.1 Rev 3, 21 CFR Part 50, 21 CFR Part 54, 21 CFR Part 56.
Key results: In all instances, the EpiAccess System functioned as intended and results observed were as expected. These test results confirm that EpiAccess System is safe, meets the design inputs, and raises no new safety or efficacy concerns.
To date there has been 100% technical success, no serious adverse events, and no adverse events related to the EpiAccess System.
Performance data demonstrate that the EpiAccess System performs as intended and is substantially equivalent to its predicates.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
K11194-, K11220-
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 870.1340 Catheter introducer.
(a)
Identification. A catheter introducer is a sheath used to facilitate placing a catheter through the skin into a vein or artery.(b)
Classification. Class II (performance standards).
0
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is a stylized image of three human profiles facing right, stacked on top of each other.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
October 29, 2014
EpiEP, Inc. % Elsa Abruzzo President & CEO Cygnus Regulatory, LLC 8 Grandin Lane Cincinnati. Ohio 45208
Re: K142245
Trade/Device Name: EpiAccess System Regulation Number: 21 CFR 870.1340 Regulation Name: Catheter Introducer Regulatory Class: Class II Product Code: DYB, DRS, DXG Dated: August 11, 2014 Received: August 13, 2014
Dear Elsa Abruzzo,
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device
1
related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Melissa A. Torres -S
For Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Indications for Use Statement
510(k) Number (if known): _ K142245
Device Name: EpiAccess System
Indications for Use:
The EpiAccess System with introducer needle and integrated needle tip pressure transducer is intended to access the epicardial surface of the heart via a subxiphoid approach to facilitate guidewire placement into the pericardial space in electrophysiology procedures in adult patients.
Prescription Use (Part 21 CFR 801 Subpart D)
AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)
Concurrence of Center for Devices and Radiological Health (CDRH)
Page 1_of 1
3
510(k) SUMMARY EpiEP, Inc.'s EpiAccess System
Submitter's Name, Address, Telephone Number, Contact Person, and Date Prepared
EpiEP, Inc.
Phone: 513-236-0857 Facsimile: 513-898-2106
Contact Person: Elsa Chi Abruzzo, RAC, FRAPS Date Prepared: October 21, 2014
Name/Address of Sponsor
EpiEP, Inc. 142 Temple Street, Suite 206 New Haven, CT 06510, USA
| Trade Name: | EpiAccess System | ||
|---|---|---|---|
| Common or Usual Name | Epicardial Introducer System | ||
| Classification Name | Introducer, Catheter | ||
| Extravascular Blood Pressure Transducer | |||
| Single-Function, Preprogrammed Diagnostic Computer | |||
| Classification: | Class II | ||
| Product Code and | |||
| Regulation: | DYB, 21 CFR 870.1340 | ||
| DRS, 21 CFR 870.2850 | |||
| DXG, 21 CFR 870.1435 | |||
| Classification Panel: | Cardiovascular | ||
| Predicate Devices: | St Jude Medical | Agilis PF Introducer System and | |
| Accessories | K11194- | ||
| Mirador | |||
| Biomedical. Inc. | Compass™ GP | ||
| Compass™ Thoracentesis | |||
| Compass™ Paracentesis | |||
| Compass™ Compartment Pressure | |||
| Compass™ Epidural Assist | |||
| Compass™ Arterial Assist | K11220- |
Intended Use / Indications for Use
The EpiAccess System with introducer needle and integrated needle tip pressure transducer is intended to access the epicardial surface of the heart via a subxiphoid approach to facilitate guidewire placement into the pericardial space in electrophysiology procedures in adult patients.
4
Technological Characteristics
The EpiAccess System consists of the following components and accessories: a sterile, single-use (disposable) Tuohy Type Needle with an integrated, distal, needle tip pressure transducer (sensor), and a reusable integrated Control Unit that includes pre-programmed diagnostic computer with a touchscreen display and graphical user interface (GUI).
The subject EpiAccess Needle is very similar or the same in design, dimensions, materials, packaging, sterilization, and intended use to the, primary predicate, the St. Jude Agilis PF Introducer. With the exception of minor dimensional differences and addition of an integrated (nonpatient contacting) fiber optic pressure transducer, the EpiAccess Needle has the same technological characteristics as the predicate introducer needle and same intended use.
The EpiAccess Control Unit provides the EpiAccess System with the additional convenience feature of integrated, direct physiological pressure measurement at the EpiAccess Needle tip. The EpiAccess Control Unit also receives input from commercially available arterial line (A-line) catheters and commercially available A-line pressure transducers. These accessories are readily available standard equipment in electrophysiology labs. A-line catheter pressure measurements are routine in electrophysiology procedures. The A-line pressure measurement function is also provided for user convenience and is displayed along with the needle tip pressure measurement on the EpiAccess user interface. The direct physiological pressure measurement functionality and indication is equivalent to that of the secondary predicate the Mirador Compass Digital Pressure Transducers (available in various models for use with various introducer needles for various anatomies).
The EpiAccess System displays the pressurement information, which phycians may be able to use to determine needle tip location based on known anatomical pressure differences. This additional information regarding needle tip location is an added convenience feature over standard Tuohy introducer needles for epicardial access. The system does not alert the user to tip location or provide clinical decision guidance. The EpiAccess Needle is placed under visualization with fluoroscopic imaging standard for electrophysiology procedures.
Performance Data
Bench, animal, and clinical tests were conducted on the EpiAccess System to demonstrate that it meets defined design requirements and can perform in a manner equivalent to devices currently on the market used for subxiphoid epicardial access and that provide pressure measurements. Testing included verification and validation testing, comparative usability testing in animals, human factors evaluations per the available guidances, and an assessment of clinical performance.
Manufacturing and traceability of devices tested were conducted in accordance with 21 CFR 820 Good Manufacturing Practices and BS EN ISO 13485:2003 Medical Devices – Quality Management Systems - Requirements for Requlatory Purposes. In all instances, the EpiAccess System functioned as intended and results observed were as expected. These test results confirm that EpiAccess System is safe, meets the design inputs, and raises no new safety or efficacy concerns. A summary of the EpiAccess Systems design control activities with regards to risk analysis and verification and validation activities is provided in this 510 (k) submission.
5
Nonclinical testing included:
Dimensional and Performance testing per the applicable sections of:
| ISO 594-2: 1998 | International Standard - Conical Fittings With 6 (Luer) Taper for Syringes, |
|---|---|
| Needles, and Certain Other Medical Equipment - Part 2: Lock Fittings | |
| SO 594-1: 1986 | International Standard - Conical Fittings With 6 (Luer) Taper For Syringes, |
| Needles, and Certain Other Medical Equipment - Part 1 General Requirements | |
| ISO 7864: 1993 | International Standard - Sterile Hypodermic Needles for Single-Use |
| ISO 9626: 2001 | International Standard - Stainless Steel Needle Tubing for The Manufacture of |
| Medical Devices - Amendment 1 | |
| BS EN ISO 14971:2012 | Medical Devices - Application of Risk Management to Medical Devices |
Electrical Safety and Electromagnetic Compatibility (EMC) per the applicable sections of:
| ANSI/AAMI/IEC 60601-
1-2:2007 | Medical Electrical Equipment - Part1-2: General Requirements for Basic Safety
and Essential Performance - Collateral Standard: Electromagnetic Compatibility
– Requirements and Tests |
|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IEC 60601-1 3rd
Edition:2012 | International Standard - Medical Electrical Equipment - General Requirements
for Basic Safety and Essential Performance |
| EN 61000 3-2: 2006 | Electromagnetic Compatibility (EMC) Part 3-2: Limits –Limits for Harmonic
Current Emissions |
| EN 61000-3-3: 2008 | Electromagnetic Compatibility (EMC) Part 3-3: Limits – Limitation of Voltage
Charges, Voltage Fluctuations and flick in low voltage supply systems. |
Pressure transducer testing per applicable sections of the recognized standards for product:
| AAMI/ANSI BP22:1994
| (R) 2011 | Blood pressure transducers |
|---|---|
| IEC 60601-2-34 Edition | |
| 3.0 2011-05 | Medical electrical equipment - Part 2-34: Particular requirements for the basic |
| safety, including essential performance, of invasive blood pressure monitoring | |
| equipment |
Biocompatibilty Testing per relevant sections of ISO 10993, including:
| BS EN ISO 10993-11:2009 | Biological Evaluation of Medical Devices – Part 11: Tests for Systemic
Toxicity (ISO 10993-11:2006) |
|-------------------------|---------------------------------------------------------------------------------------------------------|
| BS EN ISO 10993-4:2009 | Biological Evaluation of Medical Devices – Part 4: Selection of Tests for
Interactions With Blood |
| BS EN ISO 10993-5:2009 | Biological evaluation of medical devices - Part 5: test for in vitro
cytotoxicity |
| BS EN ISO 10993-10:2009 | Biological evaluation of medical devices - Part 10: Tests for irritation and
skin sensitization. |
Biocompatibilty testing passed for patient contacting materials included: L929 Neutral Red Uptake Cytotoxicity Test Kligman Maximization Test
- Intracutaneous Injection Test Systemic Injection Test Rabbit Pyrogen Test (Material Mediated) Hemolysis Rabbit Blood Complement Activation Assay
Unactivated Partial Thromboplastin Time Assay
6
Sterilization and LAL Pyrogen validation in compliance with applicable sections of:
| ANSI/AAMI/ISO 11135-1:2007 | Sterilization of Healthcare Products - Ethylene Oxide - Part 1:
Requirements for Development, Validation, and Routine Control of a
Sterilization Process for Medical Devices |
|--------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ISO 10993-7: 2008 | Biological evaluation of medical devices - Part 7: Ethylene oxide
sterilization residuals. |
| ANSI/AAMI/ISO 11737-1:
2006 | Sterilization of Medical Devices - Microbiological Methods - Part I:
Determination of a Population of Microorganisms on Products |
| ANSI/AAMI/ISO 11737-2:
2009 | Sterilization of Medical Devices - Microbiological methods - part 2: Tests
of Sterility Performed in the Validation of a Sterilization Process |
| AAMI TIR: 16:2000 | Process development and performance qualification for ethylene oxide
sterilization - Microbiological aspects |
| AAMI ST72: 2002(R) 2010 | Bacterial endotoxins - Test methodologies, routine monitoring and
alternative to batch testing. (Sterility) |
| FDA Guidance (Jun 2012) | Guidance for Industry: Pyrogen and Endotoxins Testing: Questions and
Answers |
| FDA Guidance (Dec 12, 2008) | Draft Guidance for Industry and FDA Staff: Submission and Review of
Sterility Information in Premarket Notification 510 (k) Submissions for
Devices Labeled as Sterile. |
| FDA Guidance (Aug 30, 2002) | Updated 510 (k) Sterility Review Guidance K90-1: Guidance for Industry
and FDA |
Shelf Life and Packaging validation in compliance with applicable sections of:
| ASTM F88-09 | Standard Test Method for Seal Strength of Flexible Barrier Materials |
|---|---|
| ASTM D4169-09 | Standard Practice for Performance Testing of Shipping Containers and |
| Systems | |
| ASTM F1929: 2012 | Standard Test Method for Detecting Seal Leaks in Porous Medical |
| Packaging by Dye Penetration | |
| ASTM F1980: 2007 | Standard Test Method for Accelerated Aging of Sterile Barrier Systems |
| for a Medical Device | |
| ASTM D5276: 1998 | Standard Test Method for Drop Test of Loaded Containers by Free Fall |
| ASTM D642: 2010 | Test method for determining compressive resistance of shipping |
| containers and unit loads | |
| ASTM D999:2008 | Test methods for vibration testing of shipping containers |
| ASTM D6653: 2013 | Test methods for Low Pressure (high altitude) |
| ASTM D4728: 2011 | Test methods for random vibration |
| ASTM D6344: 2009 | Test methods for concentrated impacts |
Software validation in compliance with applicable sections of:
| BS EN ISO 62304:2006 | Medical Device Software – Software Life Cycle Processes |
|---|---|
| FDA Guidance (Jan 11, 2012) | General Principles of Software Validation; Final Guidance for Industry and |
| FDA Staff | |
| FDA Guidance (Sep 9, 1999) | Off-The-Shelf Software Use in Medical Devices |
Comparative Animal Studies in compliance with applicable sections of:
| 21 CRF § 54 | Good Laboratory Practices |
|---|---|
| FDA Guidance (Jul 29, 2010) | Guidance for Industry and FDA Staff: General Considerations for Animal |
| Studies for Cardiovascular Devices |
Usability and Human Factors Testing in compliance with applicable sections of:
| SI/AAMI HE 75 | Human Factors engineering Design of Medical Devices |
|---|---|
| IEC 62366:2007 | Medical Devices - Application of Usability Engineering to Medical |
| Devices | |
| FDA Guidance (Jun 22, 2011) | Human Factors Draft Guidance |
7
Clinical data were obtained via the Epicardial Access Study. A Post Market Clinical Follow-up Study -Europe (EASe) (ClincialTrials.gov Identifier: NCT02209064). This is a European study for the purpose of collecting post marketing data of the CE Marked EpiAccess System. The study subjects are eligible adult patients undergoing epicardial electrophysiology procedures accessed via a minimally invasive subxiphoid approach. The study report supporting this notification summarizes and discusses the clinical results, including technical success (ability to safely access the pericardial space and deliver a guidewire), ease of use and clinical benefit of the pressure frequency information display, and adverse events. To date there has been 100% technical success, no serious adverse events, and no adverse events related to the EpiAccess System.
| 42 U.S.C. 282(j), Section
402(j) of the Public Health
Serve Act, enacted by 121 Stat.
| 823 Public Law 110-85 | Compliance with Clinicaltrials.gov registration |
|---|---|
| ISO 14155:2011 | International Standard - Technical Corrigendum 1 – Clinical Investigation of |
| Medical Devices for Human Subjects – Good Clinical Practice | |
| MEDDEV 2.7.1 Rev 3 | Guidelines on Medical Devices - Clinical Evaluation: A Guide for Manufacturers |
| and Notified Bodies | |
| 21 CFR Part 50 | Good Clinical Practices- Human Subject Protection |
| 21 CFR Part 54 | Financial Disclosures By Clinical Investigators |
| 21 CFR Part 56 | Good Clinical Practices - Informed Consent |
Clinical testing complies with applicable sections of:
Substantial Equivalence
The EpiAccess System has the same intended use, and similar indications for use and technological characteristics as the predicate devices. The technological characteristics of the EpiAccess Needle are substantially equivalent to the primary predicate device the St. Jude Medical Agilis PF Introducer System including packaging, biocompatibility, sterilization, and labeling. Where differences exist between the proposed device and the predicate device, performance testing demonstrated that these differences do not adversely affect the safety and effectiveness of the proposed device or different question of safety and efficacy.
The addition of integrated pressure measurement at the needle tip for an epicardial introducer needle does not change the overall intended use or raise different questions of safety and efficacy. This additional feature serves the same purpose as other separate pressure wires that can be used in conjunction with the Agilis™ PF predicate, disposable pressure transducer wires/displays that attach to introducer needles, or other devices for epicardial access. The EpiAccess simply offers the user the additional convenience of having this capability integrated with the needle component. The Mirador Compass provides similar pressure measurement capability for use with introducer needles. The addition of this feature, integrated with the EpiAccess needle, enhances user convenience and does not alter the intended use of the EpiAccess System relative to its predicates.
The results from preclinical and clinical testing demonstrate that the technological and performance characteristics of the EpiAccess System meet defined design requirements and can perform in a manner equivalent to devices currently on the market used for epicardial access and quidewire delivery and measuring physiological pressure. Performance data demonstrate that the EpiAccess System performs as intended and is substantially equivalent to its predicates.
Conclusions
The data and information presented within this submission support a determination of substantial equivalence to the predicates listed above, and therefore market clearance of the subject EpiAccess System for its intended use. This conclusion is based upon the device similarities in design, materials technological characteristics, principles of operation, and indications for use.